ENXTPA:SANPharmaceuticals
Sanofi Rare Disease Push And AI Shift Raise Long Term Questions
Sanofi's ENXTPA:SAN rilzabrutinib received breakthrough therapy designation from the US FDA for warm autoimmune hemolytic anemia.
The same drug received orphan drug designation from Japanese health authorities for this rare blood disorder.
Sanofi reported progress in its rare disease pipeline, including late stage data for venglustat in neurological Gaucher disease and regulatory steps for Rezurock in Europe.
The company is also expanding its use of AI in drug discovery and manufacturing to...